Multiple Sclerosis: How Demyelination Disrupts Nerve Signaling

Multiple sclerosis (MS) is a chronic autoimmune disorder where the immune system attacks myelin—the fatty sheath insulating nerve fibers in the central nervous system (brain, spinal cord, optic nerves).

Mechanism of Symptom Production

  • Demyelination slows or blocks nerve impulse conduction (saltatory conduction fails).
  • Axonal loss occurs over time, causing permanent disability.
  • Gliosis (sclerosis) forms plaques (lesions) visible on MRI.

Common Symptoms (Variable by Lesion Location)

  • Motor: Weakness, spasticity, paralysis.
  • Sensory: Numbness, tingling, pain (Lhermitte's sign: electric shock on neck flexion).
  • Visual: Optic neuritis (painful vision loss, color desaturation).
  • Cerebellar: Ataxia, tremor, dysarthria.
  • Autonomic: Bladder/bowel dysfunction, sexual dysfunction.
  • Cognitive: Processing speed, memory, executive function.
  • Fatigue: Overwhelming, disproportionate to activity (affects 80%).

Disease Courses

  • Relapsing-remitting (RRMS): 85% at onset; attacks with recovery.
  • Secondary progressive (SPMS): Gradual worsening after relapsing phase.
  • Primary progressive (PPMS): 15%; steady decline from onset.

Treatment Landscape

  • Disease-modifying therapies (DMTs): 20+ options (injectable, oral, infusion) reduce relapse rate, new MRI lesions, disability progression.
  • Acute relapses: High-dose IV methylprednisolone ± plasma exchange.
  • Symptomatic management: Spasticity (baclofen, botox), fatigue (amantadine, pacing), bladder (anticholinergics), pain (gabapentinoids).
  • Rehab: PT, OT, speech, cognitive rehab.

Early diagnosis and DMT initiation preserve neurological reserve. No cure yet, but outcomes have dramatically improved.

Multiple Sclerosis - Related Articles